{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:56:11Z","timestamp":1771847771506,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.7759\/cureus.85749","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:37:43Z","timestamp":1749631063000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Serum GPR-120 Levels in Diabetic Patients With and Without Nephropathy: A Comparative Study on Lipid and Renal Parameters"],"prefix":"10.7759","author":[{"given":"Divya","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejas D","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahammed Kaif","family":"Bhaniya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashishkumar M","family":"Agravatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The global epidemiology of diabetes and kidney disease","volume":"25","author":"Koye DN","year":"2018","unstructured":"Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018, 25:121-132. 10.1053\/j.ackd.2017.10.011","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165654","article-title":"Molecular pathways that drive diabetic kidney disease","volume":"133","author":"Mohandes S","year":"2023","unstructured":"Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023, 133:e165654. 10.1172\/JCI165654","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes JM","year":"2013","unstructured":"Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013, 93:137-188. 10.1152\/physrev.00045.2011","journal-title":"Physiol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-007-0036-0","article-title":"Dyslipidemia in type 2 diabetes mellitus","volume":"7","author":"Gadi R","year":"2007","unstructured":"Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep. 2007, 7:228-234. 10.1007\/s11892-007-0036-0","journal-title":"Curr Diab Rep"},{"key":"ref5","article-title":"Diabetic Nephropathy","author":"Rout P","year":"2025","unstructured":"Rout P, Jialal I. Diabetic Nephropathy. StatPearls, Treasure Island; 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens AT","year":"2013","unstructured":"Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am. 2013, 97:1-18. 10.1016\/j.mcna.2012.10.001","journal-title":"Med Clin North Am"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee M","year":"2005","unstructured":"Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005, 54:1615-1625. 10.2337\/diabetes.54.6.1615","journal-title":"Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle KR","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et al.. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014, 37:2864-2883. 10.2337\/dc14-1296","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2492-2","article-title":"GPR120: a critical role in adipogenesis, inflammation, and energy metabolism in adipose tissue","volume":"74","author":"Song T","year":"2017","unstructured":"Song T, Yang Y, Zhou Y, Wei H, Peng J. GPR120: a critical role in adipogenesis, inflammation, and energy metabolism in adipose tissue. Cell Mol Life Sci. 2017, 74:2723-2733. 10.1007\/s00018-017-2492-2","journal-title":"Cell Mol Life Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh DY","year":"2010","unstructured":"Oh DY, Talukdar S, Bae EJ, et al.. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010, 142:687-698. 10.1016\/j.cell.2010.07.041","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort RT","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al.. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013, 382:339-352. 10.1016\/S0140-6736(13)60595-4","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha V","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al.. Chronic kidney disease: global dimension and perspectives. Lancet. 2013, 382:260-272. 10.1016\/S0140-6736(13)60687-X","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67199-4_101625","article-title":"GPR120","author":"Wang Y","year":"2018","unstructured":"Wang Y, Leung PS. GPR120. Encyclopedia of Signaling Molecules.  Choi S (ed): Cham: Springer, Switzerland; 2018. 2187-2194. 10.1007\/978-3-319-67199-4_101625"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5551\/jat.12849","article-title":"Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis","volume":"20","author":"Keane WF","year":"2013","unstructured":"Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb. 2013, 20:123-133. 10.5551\/jat.12849","journal-title":"J Atheroscler Thromb"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/med.21441","article-title":"Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges","volume":"38","author":"Li Z","year":"2018","unstructured":"Li Z, Xu X, Huang W, Qian H. Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges. Med Res Rev. 2018, 38:381-425. 10.1002\/med.21441","journal-title":"Med Res Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.04.004","article-title":"Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases","volume":"32","author":"Talukdar S","year":"2011","unstructured":"Talukdar S, Olefsky JM, Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci. 2011, 32:543-550. 10.1016\/j.tips.2011.04.004","journal-title":"Trends Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2022.105348","article-title":"\u03b1-Linolenic acid regulates macrophages via GPR120-NLRP3 inflammasome pathway to ameliorate diabetic rats","volume":"99","author":"Liu Y","year":"2022","unstructured":"Liu Y, Guo M, Li Y, et al.. \u03b1-Linolenic acid regulates macrophages via GPR120-NLRP3 inflammasome pathway to ameliorate diabetic rats. J Funct Foods. 2022, 99:105348. 10.1016\/j.jff.2022.105348","journal-title":"J Funct Foods"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-00520-4","article-title":"Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy","volume":"42","author":"Wei TT","year":"2021","unstructured":"Wei TT, Yang LT, Guo F, et al.. Activation of GPR120 in podocytes ameliorates kidney fibrosis and inflammation in diabetic nephropathy. Acta Pharmacol Sin. 2021, 42:252-263. 10.1038\/s41401-020-00520-4","journal-title":"Acta Pharmacol Sin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S53892","article-title":"Potential roles of GPR120 and its agonists in the management of diabetes","volume":"8","author":"Zhang D","year":"2014","unstructured":"Zhang D, Leung PS. Potential roles of GPR120 and its agonists in the management of diabetes. Drug Des Devel Ther. 2014, 8:1013-1027. 10.2147\/DDDT.S53892","journal-title":"Drug Des Devel Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119029","article-title":"A novel GPR120-selective agonist promotes insulin secretion and improves chronic inflammation","volume":"269","author":"Yang L","year":"2021","unstructured":"Yang L, Lei XT, Huang Q, Wang T, Sun HB, Wang HY. A novel GPR120-selective agonist promotes insulin secretion and improves chronic inflammation. Life Sci. 2021, 269:119029. 10.1016\/j.lfs.2021.119029","journal-title":"Life Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2020.1768849","article-title":"Cystatin C as a biomarker of chronic kidney disease: latest developments","volume":"20","author":"Benoit SW","year":"2020","unstructured":"Benoit SW, Ciccia EA, Devarajan P. Cystatin C as a biomarker of chronic kidney disease: latest developments. Expert Rev Mol Diagn. 2020, 20:1019-1026. 10.1080\/14737159.2020.1768849","journal-title":"Expert Rev Mol Diagn"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/pathophysiology29030029","article-title":"TG\/HDL-C ratio is a risk factor associated with CKD: use in assessing the risk of progression of CKD","volume":"29","author":"Nguyen HH","year":"2022","unstructured":"Nguyen HH, Tran HH, Nguyen LT, Nguyen T, Nguyen NA, Vi MT, Nguyen KT. TG\/HDL-C ratio is a risk factor associated with CKD: use in assessing the risk of progression of CKD. Pathophysiology. 2022, 29:374-382. 10.3390\/pathophysiology29030029","journal-title":"Pathophysiology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2968869","article-title":"Oxidized LDL is associated with eGFR decline in proteinuric diabetic kidney disease: a cohort study","author":"Roumeliotis S","year":"2021","unstructured":"Roumeliotis S, Roumeliotis A, Georgianos PI, Stamou A, Manolopoulos VG, Panagoutsos S, Liakopoulos V. Oxidized LDL is associated with eGFR decline in proteinuric diabetic kidney disease: a cohort study. Oxid Med Cell Longev. 2021, 2968869. 10.1155\/2021\/2968869","journal-title":"Oxid Med Cell Longev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22639","article-title":"Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders","volume":"100","author":"Hara T","year":"2011","unstructured":"Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci. 2011, 100:3594-3601. 10.1002\/jps.22639","journal-title":"J Pharm Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2005.01.001","article-title":"Role of oxidative stress in diabetic nephropathy","volume":"12","author":"Vasavada N","year":"2005","unstructured":"Vasavada N, Agarwal R. Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis. 2005, 12:146-154. 10.1053\/j.ackd.2005.01.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3556","article-title":"Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease","volume":"38","author":"Khanijou V","year":"2022","unstructured":"Khanijou V, Zafari N, Coughlan MT, MacIsaac RJ, Ekinci EI. Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease. Diabetes Metab Res Rev. 2022, 38:e3556. 10.1002\/dmrr.3556","journal-title":"Diabetes Metab Res Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD:\u00a0conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"90","author":"Perkovic V","year":"2016","unstructured":"Perkovic V, Agarwal R, Fioretto P, et al.. Management of patients with diabetes and CKD:\u00a0conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference. Kidney Int. 2016, 90:1175-1183. 10.1016\/j.kint.2016.09.010","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211058856","article-title":"Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature","volume":"18","author":"Thipsawat S","year":"2021","unstructured":"Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature. Diab Vasc Dis Res. 2021, 18:10.1177\/14791641211058856","journal-title":"Diab Vasc Dis Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/ijosup.2014.5","article-title":"The role of omega-3 fatty acid receptor GPR120 in insulin resistance","volume":"4","author":"Oh DY","year":"2014","unstructured":"Oh DY, Walenta E. The role of omega-3 fatty acid receptor GPR120 in insulin resistance. Int J Obes Suppl. 2014, 4:S14-S16. 10.1038\/ijosup.2014.5","journal-title":"Int J Obes Suppl"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian M","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016, 316:602-610. 10.1001\/jama.2016.10924","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/362327-evaluation-of-serum-gpr-120-levels-in-diabetic-patients-with-and-without-nephropathy-a-comparative-study-on-lipid-and-renal-parameters","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T08:37:43Z","timestamp":1749631063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/362327-evaluation-of-serum-gpr-120-levels-in-diabetic-patients-with-and-without-nephropathy-a-comparative-study-on-lipid-and-renal-parameters"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.85749","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}